Skip to main content

Advertisement

SpringerLink
Log in

Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Introduction

Type 1 diabetes (T1D) is an autoimmune disease with chronic hyperglycemic state, which incidence has been globally rising during the past decades. Besides the well-known diabetic complications such as retinopathy, nephropathy and neuropathy, T1D is characterized also by poor bone health. The reduced bone mineralization, quality and strength lead to vertebral and hip fractures as the most important clinical manifestations. Suppressed bone turnover is the main characteristic of T1D-associated bone disorder.

Results

This is thought to be due to hyperglycemia, hypoinsulinemia, autoimmune inflammation, low levels of insulin-like growth factor-1 and vitamin D. Young age of T1D manifestation, chronic poor glycemic control, high daily insulin dose, low body mass index, reduced renal function and the presence of diabetic complications are clinical factors useful for identifying T1D patients at risk of reduced bone mineral density. Although the clinical risk factors for fracture risk are still unknown, chronic poor glycemic control and the presence of diabetic complications might raise the suspicion of elevated fracture risk in T1D. In the presence of the above-mentioned risk factors, the assessment of bone mineral density by dual-energy X-ray absorptiometry and the search of asymptomatic vertebral fracture by vertebral fracture assessment or lateral X-ray radiography of thorax-lumbar spine should be recommended.

Conclusion

There is no consensus about the treatment of diabetic bone disorder. However, the improvement of glycemic control has been suggested to have a beneficial effect on bone in T1D. Recently, several experiments showed promising results on using anabolic pharmacological agents in diabetic rodents with bone disorder. Therefore, randomized clinical trials are needed to test the possible use of the bone anabolic therapies in humans with T1D.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Van Belle TL, Coppieters KT, Von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91:79–118

    Article  PubMed  Google Scholar 

  2. Guariguata L (2011) Estimating the worldwide burden of type 1 diabetes. Diabetes Voice 56(2):6–8

    Google Scholar 

  3. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18:427–444

    Article  CAS  PubMed  Google Scholar 

  4. Eller-Vainicher C, Zhukouskaya VV, Tolkachev YV, Koritko SS, Cairoli E, Grossi E, Beck-Peccoz P, Chiodini I, Shepelkevich AP (2011) Low bone mineral density and its predictors in type 1 diabetic patients evaluated by the classic statistics and artificial neural network analysis. Diabetes Care 34:2186–2191

    Article  PubMed Central  PubMed  Google Scholar 

  5. Bechtold S, Dirlenbach I, Raile K, Noelle V, Bonfig W, Schwarz PH (2006) Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: data using peripheral quantitative computed tomography. Pediatrics 118:e627–e634

    Article  PubMed  Google Scholar 

  6. Saha MT, Sievanen H, Salo MK, Tulokas S, Saha HH (2009) Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers. Osteoporos Int 20:1401–1406

    Article  CAS  PubMed  Google Scholar 

  7. Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, Wang X (2009) Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 24:1618–1627

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Nyman JS, Even JL, Jo CH, Herbert EG, Murry MR, Cockrell GE, Wahl EC, Bunn RC, Lumpkin CK, Fowlkes JL, Thrailkill KM (2011) Increasing duration of type 1 diabetes perturbs the strength–structure relationship and increases brittleness of bone. Bone 48:733–740

    Article  PubMed Central  PubMed  Google Scholar 

  9. Erdal N, Gurgul S, Demirel C, Yildiz A (2012) The effect of insulin therapy on biomechanical deterioration of bone in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats. Diab Res Clin Pract 97(3):461–467

    Article  CAS  Google Scholar 

  10. Bechtold S, Putzker S, Bonfig W, Fuchs O, Dirlenbach I, Schwarz HP (2007) Bone size normalizes with age in children and adolescents with type 1 diabetes. Diabetes Care 30:2046–2050

    Article  PubMed  Google Scholar 

  11. Roggen I, Gies I, Vanbesien J, Louis O, De Schepper J (2013) Trabecular bone mineral density and bone geometry of the distal radius at the completion of pubertal growth in childhood type 1 diabetes. Horm Res Pediatr 79:68–74

    Article  CAS  Google Scholar 

  12. Armas LAG, Akhter MP, Drincic A, Recker RR (2012) Trabecular bone histomorphometry in humans with type 1 diabetes. Bone 50:91–96

    Article  PubMed Central  PubMed  Google Scholar 

  13. Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M (2009) Poor Glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int 20(6):923–933

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Neumann T, Samann A, Lodes S, Kastner B, Franke S, Kiehntopf M, Hemmelmannt C, Lehmannt L, Muller UA, Hein G, Wolf G (2011) Glycemic control is positively associated with prevalent fractures but not with bone mineral density in patients with type 1 diabetes. Diabet Med 28:872–875

    Article  CAS  PubMed  Google Scholar 

  15. Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV, Shepelkevich AP, Zhurava IV, Korolenko GG, Salko OB, Cairoli E, Beck-Peccoz P, Chiodini I (2013) Prevalence of morphometric vertebral fractures in patients with type 1 diabetes. Diabetes Care 36:1635–1640

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Retzepi M, Donos N (2010) The effect of diabetes mellitus on osseous healing. Clin Oral Implants Res 21:673–681

    Article  CAS  PubMed  Google Scholar 

  17. Starup-Linde J (2013) Diabetes, biochemical markers of bone turnover, diabetes control and bone. Front Endocrinol 4(21):1–17

    Google Scholar 

  18. McCabe LR, Zhang J, Raehtz S (2011) Understanding the skeletal pathology of type 1 and 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr 21(2):187–206

    Article  CAS  PubMed  Google Scholar 

  19. Hie M, Iitsuka N, Otsuka T, Tsukamoto I (2011) Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J Mol Med 28(3):455–462

    CAS  PubMed  Google Scholar 

  20. Zhao YF, Zeng DL, Xia LG, Zhang SM, Xu LY, Jiang XQ, Zhang FQ (2013) Osteogenic potential of bone marrow stromal cells derived from streptozotocin-induced diabetic rats. Int J Mol Med 31:614–620

    CAS  PubMed  Google Scholar 

  21. Portal-Núñez S, Lozano D, Fernández de Castro L, de Gortázar AR, Nogués X, Esbrit P (2010) Alterations of the Wnt/b-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett 584:3095–3100

    Article  PubMed  Google Scholar 

  22. Botolin S, McCabe LR (2006) Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411–424

    Article  CAS  PubMed  Google Scholar 

  23. Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M (2005) Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 1043:710–717

    Article  CAS  PubMed  Google Scholar 

  24. Fowlkes JL, Bunn RC, Thrailkill KM (2011) Contribution of insulin/insulin-like growth factor-1 axis to diabetic osteopathy. J Diabetes Metab S1(003):1–7

    Google Scholar 

  25. Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M (2007) Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40:1408–1414

    Article  CAS  PubMed  Google Scholar 

  26. Coe LM, Irwin R, Lippner D, McCabe LR (2011) The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol 226(2):477–483

    Article  CAS  PubMed  Google Scholar 

  27. Motyl KJ, Botolin S, Irwin R, Appledorn DM, Kadakia T, Amalfitano A, Schwartz RC, McCabe LR (2009) Bone inflammation and altered gene expression with type I diabetes early onse. J Cell Physiol 218:575–583

    Article  CAS  PubMed  Google Scholar 

  28. Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T (2008) Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 31:1729–1735

    Article  PubMed Central  PubMed  Google Scholar 

  29. Leger J, Marinovic D, Alberti C, Dorgeret S, Chevenne D, Levy Marchal C, Tubiana-Rufi N, Sebag G, Czernichow P (2006) Lower bone mineral content in children with type 1 diabetes mellitus is linked to female sex, low insulin-like growth factor type i levels, and high insulin requirement. J Clin Endocrinol Metab 91(10):3947–3953

    Article  CAS  PubMed  Google Scholar 

  30. Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA (2008) IGF-1 and IGF-binding proteins and bone mass, geometry and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res 23:1884–1891

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Van Sickle BJ, Simmons J, Hall R, Raines M, Ness K, Spagnoli A (2009) Increased circulating IL-8 is associated with reduced IGF-1 and related to poor metabolic control in adolescents with type 1 diabetes mellitus. Cytokine 48(3):290–294

    Article  PubMed Central  PubMed  Google Scholar 

  32. Thrailkill KM, Fowlkes JL (2013) The role of vitamin D in the metabolic homeostasis of diabetic bone. Clin Rev Bone Miner Metab 11:28–37

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Salvatoni A, Mancassola G, Biasoli R, Cardani R, Salvatore S, Broggini M, Nespoli L (2004) Bone mineral density in diabetic children and adolescents: a follow-up study. Bone 34:900–904

    Article  PubMed  Google Scholar 

  34. Pascual J, Argente J, Lopez MB, Munoz M, Martinez G, Vazquez MA, Jodar E, Perez-Cano R, Hawkins F (1998) Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int 62:31–35

    Article  CAS  PubMed  Google Scholar 

  35. Brandao FR, Vicente EJ, Daltro CH, Sacramento M, Moreira A, Adan L (2007) Bone metabolism is linked to disease duration and metabolic control in type 1 diabetes mellitus. Diabetes Res Clin Pract 78:334–339

    Article  CAS  PubMed  Google Scholar 

  36. Liu EY, Wactawski-Wende J, Donahue RP, Dmochowski J, Hovey KM, Quattrin T (2003) Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care 26:2365–2369

    Article  PubMed  Google Scholar 

  37. Gunczler P, Lanes R, Paz-Martinez V, Martins R, Esaa S, Colmenares V, Weisinger JR (1998) Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 11:413–419

    Article  CAS  PubMed  Google Scholar 

  38. Miazgowski T, Pynka S, Noworyta-Zietara M, Krzyzanowska-Swiniarska B, Pikul R (2007) Bone mineral density and hip structural analysis in type 1 diabetic men. Eur J Endocrinol 156:123–127

    Article  CAS  PubMed  Google Scholar 

  39. Joshi A, Varthakavi P, Chadha M, Bhagwat N (2013) A study of bone mineral density and its determinants in type 1 diabetes mellitus. J Osteoporos. doi:10.1155/2013/397814 Epub 2013 Mar 31

    PubMed Central  PubMed  Google Scholar 

  40. Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A (2002) The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 58(6):266–272

    Article  CAS  PubMed  Google Scholar 

  41. Heilman K, Zilmer M, Zilmer K, Tillmann V (2009) Lower bone mineral density in children with type 1 diabetes is associated with poor glycemic control and higher serum ICAM-1 and urinary isoprostane levels. J Bone Miner Metab 27(5):598–604

    Article  CAS  PubMed  Google Scholar 

  42. Camurdan MO, Cinaz P, Bideci A, Demire F (2007) Role of hemoglobin A1c, duration and puberty on bone mineral density in diabetic children. Pediatrics Int 49:645–651

    Article  CAS  Google Scholar 

  43. Munoz-Torres M, Jodar E, Escobar-Jimenez F, Lopez-Ibarra PJ, Luna JD (1996) Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin dependent diabetes mellitus. Calcif Tissue Int 58:316–319

    Article  CAS  PubMed  Google Scholar 

  44. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, Serrano Pardo MD, Garcia-Cervigon AG (2000) Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 11:455–459

    Article  CAS  PubMed  Google Scholar 

  45. Rozadilla A, Nolla JM, Montana E, Fiter J, Gomez-Vaquero C, Soler J, Roig-Escofet D (2000) Bone mineral density in patients with type 1 diabetes mellitus. Joint Bone Spine 67:215–218

    CAS  PubMed  Google Scholar 

  46. Wilkin TJ (2013) Is Autoimmunity or insulin resistance the primary driver of type 1 diabetes? Curr Diabetes Rep 13:651–656

    Article  CAS  Google Scholar 

  47. Jamal SA, Swan VJD, Brown JP, Hanley DA, Prior JC, Papaioannou A, Langsetmo L, Josse RG (2010) Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. Am J Kidney Dis 55:291–299

    Article  PubMed  Google Scholar 

  48. Morelli V, Eller-Vainicher C, Salcuni AS, Coletti F, Iorio L, Muscogiuri G, Della Casa S, Arosio M, Ambrosi B, Beck-Peccoz P, Chiodini I (2011) Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 26:1816–1821

    Article  PubMed  Google Scholar 

  49. Vestergaad P, Rejnmark L, Mosekilde L (2009) Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 84:45–55

    Article  Google Scholar 

  50. Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23(12):2735–2748

    Article  CAS  PubMed  Google Scholar 

  51. Montagnani A, Gonelli S (2013) Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab 15:784–791

    Article  CAS  PubMed  Google Scholar 

  52. Hegazy SK (2015) Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 33(2):207–212

    Article  CAS  PubMed  Google Scholar 

  53. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes (1997) Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. National Academies Press, Washington, DC

  54. Chrysant SG, Chrysant GS (2014) Controversy regarding the association of high calcium intake and increased risk for cardiovascular disease. J Clin Hypertens 16(8):545–550

    Article  CAS  Google Scholar 

  55. Wang X, Chen H, Ouyang Y, Liu J, Zhao G, Bao W, Yan M (2014) Dietary calcium intake and mortality risk from cardiovascular disease and all causes: a meta-analysis of prospective cohort studies. BMC Med 12(158):1–10

    Google Scholar 

  56. Rizzoli R, Boonen S, Brandi ML, Bruyère O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G, Reginster JY (2013) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 29(4):305–313

    Article  CAS  PubMed  Google Scholar 

  57. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96(7):1–20

    Article  PubMed  Google Scholar 

  58. Maggio ABR, Rizzoli RR, Marchand LM, Ferrari S, Beghetti M, Farpour-Lambert J (2012) Physical activity increases bone minreal density in children with type 1 diabetes. Med Sci Sports Exerc 44(7):1206–1211

    Article  PubMed  Google Scholar 

  59. Keegan THM, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL (2004) Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women. Diabetes Care 27:1547–1553

    Article  CAS  PubMed  Google Scholar 

  60. Vestergaad P, Rejnmark L, Mosekilde L (2011) Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int 88:209–214

    Article  Google Scholar 

  61. Zaheer S, LeBoff M, Lewiecki EM (2015) Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol 11(3):461–470. doi:10.1517/17425255.2015.1000860

    Article  CAS  PubMed  Google Scholar 

  62. Cairoli E, Zhukouskaya VV, Eller-Vainicher C, Chiodini I (2015) Perspectives on osteoporosis therapies. J Endocrinol Investig. doi:10.1007/s40618-014-0236-9

    Google Scholar 

  63. Motyl KJ, McCauley LK, McCabe LR (2012) Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol 227(4):1326–1334

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97(5):1737–1744

    Article  CAS  PubMed  Google Scholar 

  65. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412–420

    Article  CAS  PubMed  Google Scholar 

  66. Hamann C, Rauner M, Hohna Y, Bernhardt R, Mettelsiefen Y, Goettsch C, Gunther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28(3):627–638

    Article  CAS  PubMed  Google Scholar 

  67. Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 14:302–312

    Article  PubMed  Google Scholar 

  68. Leslie WD, Aubry-Rozier B, Lamy O, Hans D (2013) TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab 98(2):602–609

    Article  CAS  PubMed  Google Scholar 

  69. Eller-Vainicher C, Morelli V, Ulivieri FM, Palmieri S, Zhukouskaya VV, Cairoli E, Pino R, Naccarato A, Scillitani A, Beck-Peccoz P, Chiodini I (2012) Bone quality, as measured by trabecular bone score (TBS), in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J Bone Miner Res 27(10):2223–2230

    Article  CAS  PubMed  Google Scholar 

  70. Zaia A (2015) Fractal lacunarity of trabecular bone and magnetic resonance imaging: new perspectives for osteoporotic fracture risk assessment. World J Orthop 6(2):221–235

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

Volha V. Zhukouskaya, Cristina Eller-Vainicher, Alla P. Shepelkevich, Yulia Dydyshko, Elisa Cairoli and Iacopo Chiodini declare that they have no conflict of interest.

Ethical approval

All the studies cited in the current mini review involving human participants and/or animal models have received ethical approval.

Informed consent

All human participants before entering in the research gave their informed consent.

Author information

Authors and Affiliations

  1. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    V. V. Zhukouskaya, C. Eller-Vainicher, E. Cairoli & I. Chiodini

  2. Unit of Endocrinology and Metabolic Disease, Foundation IRCCS Cà Granda, Ospedale Maggiore Policlinico, Padiglione Granelli, F. Sforza Street, 35, 20122, Milan, Italy

    V. V. Zhukouskaya, C. Eller-Vainicher, E. Cairoli & I. Chiodini

  3. Divisione di Endocrinologia, Dipartimento di Medicina Clinica e Chirurgia, University of Naples Federico II, Pansini Street, 5, 80131, Naples, Italy

    V. V. Zhukouskaya

  4. Belarusian State Medical University, Endocrinology Chair, Minsk, Belarus

    A. P. Shepelkevich & Y. Dydyshko

Authors
  1. V. V. Zhukouskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Eller-Vainicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. P. Shepelkevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Dydyshko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Cairoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Chiodini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. V. Zhukouskaya.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhukouskaya, V.V., Eller-Vainicher, C., Shepelkevich, A.P. et al. Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice. J Endocrinol Invest 38, 941–950 (2015). https://doi.org/10.1007/s40618-015-0284-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-015-0284-9

Keywords

Search

Navigation